Skip to content

Study Protocol Comparing Polidocanol Versus Hypertonic Glucose for Treatment of Reticular Veins

A Randomized Triple-blind Study Protocol Comparing Polidocanol Versus Hypertonic Glucose for Sclerotherapy in Treatment of Reticular Veins at the Lower Limbs.

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02054325
Enrollment
106
Registered
2014-02-04
Start date
2012-09-30
Completion date
2014-12-31
Last updated
2017-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Varicose Veins

Keywords

Sclerotherapy, varicose veins, veins

Brief summary

It will be done a randomized triple-blind study comparing 0,2% polidocanol versus 75% hypertonic glucose of sclerotherapy in lower limbs´ reticular veins. It will be included only adult women with reticular veins on the side of the thighs and mild venous insufficiency (CEAP 1). The primary endpoint will be efficacy, and secondary will be safety.

Detailed description

Background. The prevalence of chronic venous disease is high in the general population, mainly in young women, and in milder cases the usual complaint is aesthetic. Various techniques are used for treatment of mild varicose disease, including surgical treatment, laser ablation and sclerotherapy. Reticular veins are those with less than 3mm diameter, bluish and important contribution to the aesthetic damage, and sometimes they are related to local pain and recurrence after treatment of telangiectasias. There is no consensus in the literature about the effectiveness of treatment with sclerotherapy, despite of being an usual procedure with different chemicals. Methods and design. One hundred lower limbs of healthy women between 18 and 69 years will be triple blind randomized to receive treatment with polidocanol 0.2% diluted in 70% hypertonic glucose versus 75% hypertonic glucose for sclerotherapy treatment of reticular veins. The patients will be examined and clinically classified. It will be included patients with reticular veins sited at out's thigh/leg, measuring at least 10cm long, and only one extremity will be included per patient. The patients with varicose disease CEAP 2 or more will not be included. The treatment will be carried out in only one session and the medication volume not exceeding 5 ml. Clinical follow-up protocols will be filled on regular visits on days 0 - 7 - 60 concomitantly with photograph documentation. Supplementary examination for venous mapping with ultrasound pretreatment is performed for all patients. Discussion. This prospective controlled double-blind randomized trial aims to verify and compare the efficacy and safety for sclerotherapy treatment of reticular veins of the lower limbs. The results may help physicians to choose the best sclerotherapy treatment for reticular veins.

Interventions

An application session 0.2% Polidocanol + 70% Glucose to treat reticular veins of the lower limb selected, with a maximum volume of 5 ml. Return to a week to investigate the adverse effects and 2 months for proof of efficacy and adverse effects

DRUGGlucose

An application session 75% Glucose to treat reticular veins of the lower limb selected, with a maximum volume of 5 ml. Return to a week to investigate the adverse effects and 2 months for proof of efficacy and adverse effects

Sponsors

Fundação de Amparo à Pesquisa do Estado de São Paulo
CollaboratorOTHER_GOV
UPECLIN HC FM Botucatu Unesp
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 69 Years
Healthy volunteers
No

Inclusion criteria

* females * with at least 10 cm from the lateral reticular veins of the leg or thigh of the leg * clinical classification of chronic venous disease C1(mild venous disease), * minimum age of 18 year-old and maximum age 69 year-old * agreement with the study * signing the free and informed consent ( IC) * not use anticoagulant drugs .

Exclusion criteria

* male * varicose disease in any quantity or location with clinical classification of chronic venous disease different of C1(mild venous disease) * restrict mobility * arterial insufficiency * be allergic to any substance that may be related to the study drugs * any cause of dermatitis on application site * free of comorbidities clinically serious as diabetes mellitus, heart failure, respiratory failure, uncontrolled hypertension with medication, and uncontrolled hypothyroidism * pregnancy * previous deep vein thrombosis (DVT) * family history of DVT * thrombophilia * do not agree with the search terms

Design outcomes

Primary

MeasureTime frameDescription
Efficacy in Treating Reticular Veins by Photographs: Mean Percent Reticular Vein Disappearance Two Months After Treatment.Mean Percent of reticular vein disappearance two months after treatmentPhotographs were performed pretreatment and two months after the treatment, these were analyzed for efficacy in treat reticular veins by two blind analyzers objectively with measurement through the use of free software ImageJ.

Secondary

MeasureTime frameDescription
The Safety of the Treatment: Mean Percent of Skin Hyperpigmentation Two Months After TreatmentTwo months after treatment.Skin hyperpigmentation was defined as a brownish hue stain superimposing the previous treated vein site (by visual photographic analyses). Skin hyperpigmentation was firstly evaluated according to its occurence and labeled as Yes or No. Afterwards, when there was stain in the previous treated area, a line was drawn on the stain with Image J software , and the Mean Percent of Skin Hyperpigmentation was proportionaly compared with length of vein treated, previuos mesuread (mean and SD).

Countries

Brazil

Participant flow

Pre-assignment details

Some patients (n=6) were withdrawn because did not appear at the previous scheduled appointments, and were replaced for new ones. In order to avoid loss of individuals we have decided to include 6 more patients.

Participants by arm

ArmCount
Polidocanol With Glucose
An application session 0.2% Polidocanol + 70% Glucose to treat reticular veins of the lower limb selected, with a maximum volume of 5 ml. Polidocanol with Glucose: An application session 0.2% Polidocanol + 70% Glucose to treat reticular veins of the lower limb selected, with a maximum volume of 5 ml. Return to a week to investigate the adverse effects and 2 months for proof of efficacy and adverse effects
43
Glucose
An application session 75% Glucose to treat reticular veins of the lower limb selected, with a maximum volume of 5ml. Glucose: An application session 75% Glucose to treat reticular veins of the lower limb selected, with a maximum volume of 5 ml. Return to a week to investigate the adverse effects and 2 months for proof of efficacy and adverse effects
50
Total93

Withdrawals & dropouts

PeriodReasonFG000FG001
Overall StudyLost to Follow-up85

Baseline characteristics

CharacteristicPolidocanol With GlucoseGlucoseTotal
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
0 Participants0 Participants0 Participants
Age, Categorical
Between 18 and 65 years
43 Participants50 Participants93 Participants
Gender
Female
43 Participants50 Participants93 Participants
Gender
Male
0 Participants0 Participants0 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
— / —— / —
other
Total, other adverse events
22 / 4331 / 50
serious
Total, serious adverse events
0 / 430 / 50

Outcome results

Primary

Efficacy in Treating Reticular Veins by Photographs: Mean Percent Reticular Vein Disappearance Two Months After Treatment.

Photographs were performed pretreatment and two months after the treatment, these were analyzed for efficacy in treat reticular veins by two blind analyzers objectively with measurement through the use of free software ImageJ.

Time frame: Mean Percent of reticular vein disappearance two months after treatment

ArmMeasureValue (MEAN)Dispersion
Polidocanol With GlucoseEfficacy in Treating Reticular Veins by Photographs: Mean Percent Reticular Vein Disappearance Two Months After Treatment.95.17 % of Reticular Veins that DisappearedStandard Deviation 9.09
GlucoseEfficacy in Treating Reticular Veins by Photographs: Mean Percent Reticular Vein Disappearance Two Months After Treatment.85.40 % of Reticular Veins that DisappearedStandard Deviation 17.04
Secondary

The Safety of the Treatment: Mean Percent of Skin Hyperpigmentation Two Months After Treatment

Skin hyperpigmentation was defined as a brownish hue stain superimposing the previous treated vein site (by visual photographic analyses). Skin hyperpigmentation was firstly evaluated according to its occurence and labeled as Yes or No. Afterwards, when there was stain in the previous treated area, a line was drawn on the stain with Image J software , and the Mean Percent of Skin Hyperpigmentation was proportionaly compared with length of vein treated, previuos mesuread (mean and SD).

Time frame: Two months after treatment.

ArmMeasureValue (MEAN)Dispersion
Polidocanol With GlucoseThe Safety of the Treatment: Mean Percent of Skin Hyperpigmentation Two Months After Treatment5.75 Percent of Skin HyperpigmentationStandard Deviation 7.02
GlucoseThe Safety of the Treatment: Mean Percent of Skin Hyperpigmentation Two Months After Treatment9.66 Percent of Skin HyperpigmentationStandard Deviation 11.67

Source: ClinicalTrials.gov · Data processed: Mar 18, 2026